Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma-Reference-Cited by-同舟云学术

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Published:2014-05-15 Issue:20 Volume:123 Page:3073-3079
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Martinez-Lopez Joaquin¹,Lahuerta Juan J.¹,Pepin François²,González Marcos³,Barrio Santiago¹,Ayala Rosa¹,Puig Noemí³,Montalban María A.¹,Paiva Bruno⁴,Weng Li²,Jiménez Cristina³,Sopena María¹,Moorhead Martin²,Cedena Teresa¹,Rapado Immaculada¹,Mateos María Victoria³,Rosiñol Laura⁵,Oriol Albert⁶,Blanchard María J.⁷,Martínez Rafael⁸,Bladé Joan⁵,San Miguel Jesús⁴,Faham Malek²,García-Sanz Ramón³

Affiliation:

1. Hospital Universitario 12 de Octubre, Madrid, Spain;

2. Sequenta, Inc., San Francisco, CA;

3. Hospital Universitario de Salamanca-IBSAL, IBMCC-CSIC, Salamanca, Spain;

4. Clínica Universitaria de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain;

5. Hospital Clínic i Provincial de Barcelona, Institut d'Investigacions Biomédiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;

6. Hospital Germans Trias i Pujol, Barcelona, Spain;

7. Hospital Ramón y Cajal, Madrid, Spain; and

8. Hospital Clínico de Madrid, Madrid, Spain

Abstract

Key Points MRD assessment by sequencing is prognostic of TTP and OS in multiple myeloma patients. Among patients in complete response, MRD assessment by sequencing enables identification of 2 distinct subgroups with different TTP.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/20/3073/1376625/3073.pdf

Reference50 articles.

1. Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy.;Corso;Haematologica,1999

2. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists’ Collaborative Group.;J Clin Oncol,1998

3. Improved survival in multiple myeloma and the impact of novel therapies.;Kumar;Blood,2008

4. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.;Barlogie;Blood,1986

5. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.;Bladé;Br J Haematol,1998

Cited by 344 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Single-Tube Next Generation Sequencing Assay for B-Cell Receptor Clonality Testing;Journal of Molecular Pathology;2024-02-02

2. Measurable Residual Disease and Decision-Making in Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-01

3. Modern approaches to assessment of minimal residual disease in multiple myeloma (plasma cell myeloma) cases;Medicine of Extreme Situations;2023-12

4. Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms;The Journal of Molecular Diagnostics;2023-12

5. Aiming for the cure in myeloma: Putting our best foot forward;Blood Reviews;2023-11